Background: Allergen-mediated cross-linking of IgE on mast cells/basophils is a well-recognized trigger for type 1 allergic diseases such as allergic rhinitis (AR). However, allergens may not be the sole trigger for AR, and several allergic-like reactions are induced by non-IgE-mediated mechanisms. Objective: We sought to describe a novel non-IgE-mediated, endotoxin-triggered nasal type-1-hypersensitivity-like reaction in mice. Methods: To investigate whether endotoxin affects sneezing responses, mice were intraperitoneally immunized with ovalbumin (OVA), then nasally challenged with endotoxin-free or endotoxin-containing OVA. To investigate the role of T cells and mechanisms of the endotoxin-induced response, mice were adoptively transferred with in vitro-differentiated OVA-specific T H 2 cells, then nasally challenged with endotoxin-free or endotoxin-containing OVA. Results: Endotoxin-containing, but not endotoxin-free, OVA elicited sneezing responses in mice independent from IgE-mediated signaling. OVA-specific T H 2 cell adoptive transfer to mice demonstrated that local activation of antigen-specific T H 2 cells was required for the response. The Toll-like receptor 4-myeloid differentiation factor 88 signaling pathway was indispensable for endotoxin-containing OVA-elicited rhinitis. In addition, LPS directly triggered sneezing responses in OVA-specific T H 2-transferred and nasally endotoxin-free OVA-primed mice. Although antihistamines suppressed sneezing responses, mast-cell/basophil-depleted mice had normal sneezing responses to endotoxin-containing OVA. Clodronate treatment abrogated endotoxin-containing OVA-elicited rhinitis, suggesting the involvement of monocytes/ macrophages in this response. Conclusions: Antigen-specific nasal activation of CD4 1 T cells followed by endotoxin exposure induces mast cell/basophilindependent histamine release in the nose that elicits sneezing responses. Thus, environmental or nasal residential bacteria may exacerbate AR symptoms. In addition, this novel phenomenon might explain currently unknown mechanisms in allergic(-like) disorders. (J Allergy Clin Immunol 2017;139:258-68.) Key words: Allergic rhinitis, CD4
Type 1 hypersensitivity reactions are a major pathological response in allergic diseases such as allergic rhinitis (AR), allergic asthma, and allergic anaphylaxis. 1 Classical type 1 hypersensitivity reactions are mediated by mast cells and basophils armed with antigen-specific IgE. 1, 2 Cross-linking of IgE on mast cells/basophils by cognate antigens induces degranulation and the release of chemical mediators including histamine, which elicits bronchoconstriction and vasodilation and increases vascular permeability. 2 Although the IgE-mastcell-mediated pathway is closely linked to allergic disorders, several type-1-hypersensitivity-like symptoms are induced by non-IgE-mediated mechanisms. [3] [4] [5] The early-phase responses of AR (eg, sneezing) are mainly induced by allergen-mediated IgE cross-linking on mast cells. 6 However, the allergen-IgE pathway may not be the sole trigger, because some patients with AR do not respond to anti-IgE therapy. 7 Currently, non-IgE-mediated trigger(s) of AR symptoms are entirely unknown. AR diagnosis is based on rhinitis symptoms: sneezing, nasal discharge, and nasal clotting, and the presence of systemic or local (nasal) allergen-specific IgE. [8] [9] [10] Patients with rhinitis without allergen-specific IgE are diagnosed as suffering from nonallergic rhinitis (NAR) and, in most cases, triggers of the symptoms are unclear. 11 Although NAR is not considered an allergy, some patients with NAR show nasal infiltration of inflammatory cells including neutrophils, eosinophils, and mast cells that suggests local activation of innate and/or adaptive immunity. [12] [13] [14] [15] In addition, histamine, a major mediator of type 1 allergic reactions, is involved in the disease symptoms, because antihistamines are often effective in patients with NAR. 11 Thus, the nasal symptoms of NAR with inflammation might be an immune-mediated hypersensitivity reaction. Currently, the underlying pathological mechanisms in these non-IgE-mediated allergic reactions have been rarely studied. Although IgE cross-linking is the classical signal for mast cell/basophil degranulation, 1,2 many signals induce IgE-independent mast cell degranulation. 4, 16 In addition, many cell types other than mast cells/basophils can produce and release histamine by non-IgE-mediated mechanisms. [17] [18] [19] [20] [21] [22] These observations prompted us to investigate the causes and mechanisms of non-IgE-mediated type-1-hypersensitivity-like reactions.
LPS, also known as endotoxin, is a component of the gramnegative bacterial cell wall and is a common contaminant in several allergens including household dust [23] [24] [25] and animal dander, 26, 27 as well as ambient air pollutants. 28 Low-dose LPS is a well-known T H 2-inducing adjuvant in airway application models. 29, 30 Furthermore, several allergens contain ligands for Toll-like receptor 4 (TLR4), the LPS receptor, which mediates their allergenicity. [31] [32] [33] Even though mast cells also express TLR4, and LPS stimulation of mast cells induces cytokine production, LPS does not elicit mast cell degranulation. 34 Thus, even though LPS can participate in some allergic sensitizations, it is not considered a trigger of effector-phase responses.
In this study, we show the presence of a hitherto unknown non-IgE-mediated nasal allergy-like response in mice. Nasal application of endotoxin-containing ovalbumin (OVA) (Ec-OVA) triggers sneezing, a type-1-hypersensitivity-like reaction, in mice, which is IgE-and mast-cell-independent, but dependent on CD4 1 T cells, histamine, and monocytes/macrophages. We propose that the local activation of antigen-specific CD4 1 T cells followed by endotoxin exposure can elicit histamine release in the nose that triggers a type-1-hypersensitivity-like reaction. This reaction might contribute to classical and non-IgE-mediated allergic disorders of which the pathological mechanisms are not fully understood.
METHODS
More detailed methods can be found in this article's Methods section in the Online Repository at www.jacionline.org.
Mice
BALB/c wild-type (WT) mice were purchased from Charles River Laboratories Japan (Yokohama, Japan 
Removal of endotoxin from OVA
Endotoxin-free ovalbumin (Ef-OVA) was generated from commercially available Ec-OVA. Overall, 1 mL of OVA solution (20 mg/mL) was mixed with 10 mL of Triton X-114 by vortexing. Samples were placed on ice for 5 minutes, then incubated at 378C for 5 minutes. After centrifugation (9000g for 7 seconds), the upper aqueous phases were collected. The procedure was repeated 3 times. Residual detergent in the aqueous phase was removed by Pierce Detergent Removal Spin Columns (Pierce Biotechnology, Rockford, Ill). The endotoxin levels in Ec-OVA and Ef-OVA were determined by Pierce LAL Chromogenic Endotoxin Quantitation Kit (Pierce Biotechnology). Endotoxin levels in OVAs used in this study were 100 to 207 EU/mg (Ec-OVA) and 1.74 EU/mg (Ef-OVA), where 1 EU is equivalent to 0.1 ng of LPS from Escherichia coli E111:B4.
Mouse models
For the OVA immunization model, mice were injected intraperitoneally (i.p.) with a mixture of Ef-OVA (30 mg/200 mL/mouse) and alum (1 mg/200 mL/mouse) in PBS on days 218, 211, and 24. Five days after the final immunization (day 1), mice were intranasally (i.n.) administered 20 mL of PBS, Ec-OVA, or Ef-OVA (1 mg protein/dose in PBS) for 4 consecutive days. For cell-transfer models, mice were injected intravenously with naive or in vitro-differentiated OVA-specific T H 2 cells from DO11. 10 1 CD4 1 T cells (4-6 3 10 6 cells) on day 21. Two days after the transfer (day 1), mice were i.n. administered 20 mL of PBS, Ec-OVA, or Ef-OVA (1 mg protein/dose in PBS) for 4 consecutive days. Memory T H 2 cells were generated in mice transferred with DO11. 10 1 T H 2 cells, and these were then left untreated for 6 weeks. In some experiments, mice were i.n. administered 20 mL of LPS (0.5, 5, or 50 ng/mL in PBS 
Statistics
Two-tailed Student t test and 1-way ANOVA followed by Tukey test were used to determine the statistical significance between 2 groups and among more than 2 groups, respectively. Two-way ANOVA followed by Bonferroni test was used for analyzing statistics of time-course experiments. P values of less than .05 were considered statistically significant.
RESULTS

Ec-OVA elicits IgE-independent rhinitis
We investigated whether AR-like symptoms can be elicited by non-IgE-mediated mechanisms. WT and Fcer1a 2/2 mice, deficient for FcεRI and thus deficient for IgE-mediated allergic reactions, 9,37 were i.p. immunized with Ef-OVA 3 times (days 218, 211, and 24), then i.n. challenged with 1 mg of Ef-OVA (endotoxin level, 1.74 EU/mg) or Ec-OVA (endotoxin level, 100-207 EU/mg) for 4 consecutive days (days 1-4) (Fig 1, A) . Ef-OVA-challenged WT mice showed increased sneezing from the second day, whereas Fcer1a 2/2 mice had levels of sneezing similar to those of PBS-challenged mice, indicating that the response was IgE-dependent (Fig 1, B) . However, when mice were challenged with Ec-OVA, both WT and Fcer1a 2/2 mice showed similar increases in sneezing (Fig 1, C) . Thus, pure antigens elicit rhinitis only via an IgE-dependent mechanism, whereas endotoxin-containing antigens can elicit non-IgE-mediated rhinitis in mice.
CD4
1 T-cell activation is required for inducing Ec-OVA-elicited rhinitis
To investigate the requirement of antigen-specific CD4
1
T cells for the induction of Ec-OVA-elicited rhinitis, we used an OVA-specific T H 2 cell adoptive transfer model. DO11.10 1 mice-derived naive CD4 1 T cells, which express an OVA 323-339 -specific T-cell receptor, were in vitro differentiated into T H 2 cells (OVA-T H 2). The cells were adoptively transferred into naive recipient mice (day 21) followed by intranasal challenge with Ef-OVA or Ec-OVA from 2 days after the transfer (days 1-4) (Fig 2, A) . Ec-OVA challenge elicited sneezing responses in OVA-T H 2-transferred, but not nontransferred (Fig 2, B) or naive OVA-specific CD4 (Fig 2, E) , but induced nasal OVA-T H 2 accumulation comparable to that with Ec-OVA challenge (Fig 2, F) . Likewise, nasal eosinophilia was comparably induced in figure) . N.S., Not significant. **P < .01; ***P < .001.
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Ef-OVA-and Ec-OVA-challenged mice (Fig 2, G) . These results demonstrated that the development of antigen-specific T H 2 cells and their local activation were essential for inducing Ec-OVA-elicited rhinitis, but the antigen alone was insufficient to trigger sneezing. Group 2 innate lymphoid cells (ILC2s) are implicated in several allergic diseases as an innate type 2 cytokine producer. 38 However, the frequency of ILC2s among the noses from PBS-, Ec-OVA-, and Ef-OVA-challenged mice was not To investigate whether Ec-OVA-elicited rhinitis in OVA-T H 2-transferred mice was IgE-independent, as for the OVA immunization model (Fig 1) , we transferred OVA-T H 2 cells into Fcer1a 2/2 and T-and B-cell-deficient Rag2 2/2 mice. Both Fcer1a 2/2 (Fig 2, H) and Rag2 2/2 mice (Fig 2, I ) had a comparable frequency of sneezing to that of WT mice in response to Ec-OVA. Therefore, neither IgE nor other antibody-mediated signals were involved in Ec-OVA-elicited rhinitis.
Local CD4
1 T-cell activation followed by LPS stimulation triggers rhinitis Next, we investigated whether endotoxin-mediated sneezing responses are induced through the conventional TLR4 signaling pathway. Ec-OVA challenge failed to elicit sneezing in OVA-T H 2-transferred Tlr4 2/2 (Fig 3, A) and Myd88 2/2 mice (Fig 3, B) . Nevertheless, nasal OVA-T H 2 accumulation in Tlr4 2/2 (Fig 3, C) and Myd88 2/2 (Fig 3, D) mice was comparable to that in WT mice. In addition, Tlr4 2/2 (Fig 3, E) and Myd88 2/2 (Fig 3, F ) mice showed substantial, although partially reduced, nasal eosinophilia in response to Ec-OVA challenge. These results indicated that although TLR4-MyD88 signaling contributed to local T H 2 activation, antigen stimulation alone could induce substantial nasal accumulation and activation of T H 2 cells. In addition to activating T H 2 cells, activation of the TLR4-MyD88 pathway in cells of recipient mice was critical for triggering sneezing responses.
Because TLR4-MyD88 signaling played a critical role in eliciting sneezing in our model, we investigated whether LPS could directly trigger sneezing. OVA-T H 2-transferred mice were challenged with Ec-OVA for 4 days, or Ef-OVA for 2 days (days 1 and 2), followed by LPS (50 ng/mL) challenge on days 3 and 4 (Fig 4, A) . As shown in Fig 4, B, Ef-OVA followed by LPS challenge elicited sneezing comparable to that with Ec-OVA challenge on day 3. However, at day 4, although Ec-OVA-challenged mice maintained high sneezing levels, LPS challenge alone failed to elicit sneezing (Fig 4, B) . Mice challenged with Ef-OVA (days 1-2) and left on day 3 also did not respond to LPS challenge at day 4 (see Fig E5 in this article's Online Repository at www.jacionline.org), suggesting that the time after nasal CD4 1 T-cell activation was important to elicit sneezing by LPS challenge. To determine the LPS concentration required to elicit sneezing, Ef-OVA-primed mice were challenged with several doses of LPS (Fig 4, A, Ef-OVA/LPS). Doses of 0.5 and 5 ng/mL LPS had some effect, while 50 ng/mL LPS elicited substantial levels of sneezing (Fig 4, C) .
Taken together, these observations clearly demonstrate that LPS directly triggers sneezing responses, but antigen-dependent local activation of CD4 1 T cells is a prerequisite and is also essential for maintaining the response.
Mast cell/basophil-independent histamine mediates Ec-OVA-elicited rhinitis
Histamine release is central to sneezing responses in AR, 8 and antihistamines are also effective in patients with 4) . B and C, Number of sneezes at days 3 and 4 was counted for 10 minutes immediately after i.n. challenge. Pooled data from 3 (Fig 4, B) or 2 (Fig 4, C) independent experiments are shown (mean, SEM, n 5 indicated in figure) . N.S., Not significant. ***P < .001.
non-IgE-mediated rhinitis. 11 Thus, to investigate whether histamine mediates Ec-OVA-elicited rhinitis, mice were i.p. injected with antihistamines, diphenhydramine or fexofenadine, 90 -minutes before Ec-OVA challenge. Diphenhydramine (Fig 5; see Fig E6, A, in this article's Online Repository at www. jacionline.org) and fexofenadine (Fig E6, B) completely suppressed Ec-OVA-elicited sneezing, demonstrating that histamine release mediated the Ec-OVA-elicited rhinitis similar to that in classical IgE-mediated type 1 hypersensitivity reactions.
Mast cells and basophils are major sources of histamine in classical allergic responses, 2, 8 and their degranulation can also be induced by non-IgE-mediated mechanisms. 4 Therefore, we investigated the involvement of mast cells and basophils in Ec-OVA-elicited rhinitis. Mas-TRECK mice, a transgenic mouse strain expressing the human DT receptor gene under the control of a mouse mast cell-specific Il4 intronic enhancer, 39 were i.p. injected with DT (Fig 6, A) . As previously demonstrated in the peritoneal cavity or skin, 39 both mast cells and basophils were completely depleted from the noses of DT-injected Mas-TRECK mice, as assessed by nasal mRNA levels of Mcpt1, Mcpt2 (markers for mucosal mast cells), and Mcpt8 (a marker for basophils) (see Fig E7, A, in this article's Online Repository at www.jacionline.org). Although IgE-mediated sneezing responses (induced by OVA sensitization followed by Ef-OVA challenge) were completely abrogated in DT-treated Mas-TRECK mice (Fig E7, B and C) , OVA-T H 2-transferred and DT-injected Mas-TRECK mice showed increased sneezing in response to Ec-OVA challenge comparable to that of OVA-T H 2-transferred and DT-injected WT mice (Fig 6, B) . In addition, mast cell-and basophil-depleted noses still had substantial histidine decarboxylase mRNA expression, an enzyme that catalyzes the reaction for histamine synthesis (Fig E7, A) . Therefore, although histamine was required for Ec-OVA-elicited rhinitis, the cellular source(s) was not mast cells or basophils.
Monocytes/macrophages are involved in Ec-OVAelicited rhinitis
We next investigated whether other cell types might mediate Ec-OVA-elicited rhinitis. Monocytes/macrophages were depleted from OVA-T H 2-transferred and Ec-OVA-challenged mice by intraperitoneal injection of clodronate-containing liposomes on day 3, 6 hours after the third OVA challenge (Fig  7, A) (Fig 7, C) . Clodronate treatment completely abrogated sneezing responses in OVA-immunized and Ec-OVAchallenged Fcer1a 2/2 mice at day 4 in which IgE signaling did not mediate the sneezing (Fig 7, D) . Clodronate partially, but significantly, reduced the sneezing responses in Ec-OVAchallenged WT mice in which both IgE and endotoxin mediated the sneezing (Fig 7, E) , although it did not affect the sneezing responses in Ef-OVA-challenged WT mice in which only IgE mediated the sneezing (Fig 7, F) . These results demonstrated that clodronate treatment abrogated endotoxin-mediated, but not IgE-mediated, sneezing responses. Therefore, monocytes and macrophages are specifically involved in endotoxin-elicited rhinitis.
DISCUSSION
In this study, we report a previously unknown nasal type-1-hypersensitivity-like reaction in mice. Nasal activation of antigen-specific CD4 1 T cells followed by LPS challenge induced rhinitis symptoms. The sneezing response was mediated challenged with Ec-OVA (Fig 7, D and E) or Ef-OVA (Fig 7, F) . On day 3, 6 hours after the third nasal challenge, mice were i.p. injected with PBS or clodronate-containing liposome. D-F, Number of sneezes was counted for 10 minutes immediately after each intranasal challenge. Pooled data from 2 independent experiments are shown (mean, SEM, n 5 indicated in figure) . N.S., Not significant. **P < .01; ***P < .001.
by histamine, but the cellular source(s) was not mast cells or basophils. This is the first report to demonstrate that LPS elicits histamine-mediated hypersensitivity-like reactions in the nose. Although allergen-mediated IgE-cross-linking is central to AR pathogenesis, it may not be the sole trigger of AR. Nasal provocation tests with an allergen plus LPS enhanced nasal responses and increased total nasal resistance and clinical scores in children with AR compared with allergen alone. 40 In addition, high-dose nasal LPS challenge (;500 mg/mL) induced mild nasal symptoms such as itching or nasal secretion, even in nonallergic individuals. 41, 42 In this study, we showed that even low-dose LPS (50 ng/mL) directly triggered sneezing responses in nasally T H 2-activated mice. Thus, the previously demonstrated LPS-mediated augmentation of nasal responses in children with AR 40 might be caused by direct LPS-triggered responses in addition to classical antigen-IgE-mediated responses. Because LPS concentration that elicited sneezing in this study was within the range of endotoxin levels found in extracts from household dust, [25] [26] [27] endotoxin-elicited reactions might mediate rhinitis symptoms in actual disease settings of AR. In addition, LPS or microbial products are also found in ambient air particles that are considered important exacerbation factors for respiratory allergy. 28 Although treatment with an anti-IgE mAb, omalizumab, significantly improved AR symptoms, there were a substantial number of patients with AR who did not respond to therapy. 7 Omalizumab-unresponsive rhinitis symptoms might be mediated by allergens contaminated with endotoxin or environmental pollutants.
In addition to classical AR, endotoxin-elicited rhinitis might mediate some disease settings of NAR. NAR is diagnosed by the presence of persistent rhinitis symptoms with negative antigenspecific IgE and/or skin prick test result. 11 Patients with NAR may include patients misdiagnosed with local AR whose symptoms are indeed mediated by locally (nasally) detectable allergenspecific IgE. 10 Some patients with authentic NAR, who really do not have allergen-specific IgE, even show nasal infiltration of inflammatory cells. [12] [13] [14] [15] This NAR with inflammation can be further classified into differential subtypes, such as NAR with eosinophilia syndrome or NAR with neutrophils, on the basis of infiltrating cell types. [12] [13] [14] [15] Among them, our mouse model best resembled NAR with eosinophilia syndrome: nasal eosinophilic inflammation with IgE-independent rhinitis symptoms. Furthermore, rhinitis symptoms of NAR can often be controlled by antihistamines, 11 which were also effective in our mouse model. Whether T cells are activated in the noses of patients with NAR with inflammation is currently unknown. However, because the classification of ''nonallergic'' is based on the absence of antigen-specific IgE and/or a negative skin prick test result, it might be useful to examine the presence of activated T cells in the noses of patients with NAR with inflammation, especially patients with NAR with eosinophilia syndrome. Another potential consideration is ILC2-mediated inflammation. Even though we did not find potential involvement of ILC2s in our model, nasal inflammation of some patients with NAR might be induced by ILC2, but not T-cell, activation. And the presence of local inflammation might be sufficient to induce endotoxinelicited rhinitis.
Whether the endotoxin-elicited reaction demonstrated here could be induced in organs other than nose is currently unclear. Some patients with food allergy, mainly infants or young children, are diagnosed with non-IgE-mediated gastrointestinal food allergies. 3 The patients manifest food allergy symptoms, vomiting and diarrhea after ingestion of offending foods, yet show negative skin prick test results and serum specific IgE against the food antigens. 3 Although T cells are assumed to play a role in the disease, its pathogenesis is poorly understood. 3 Therefore, it would be of interest to investigate the involvement of endotoxin-elicited reactions in several non-IgE-mediated allergic disorders including non-IgE-mediated gastrointestinal food allergies.
Mast cells and basophils are the major sources of histamine in allergic reactions. 43 However, the present study showed that they were not involved in Ec-OVA-elicited rhinitis because DT-treated Mas-TRECK mice had a frequency of sneezing comparable to that of DT-treated WT mice. Other than these cell types, several hematopoietic cell types (macrophages, 17 neutrophils, 18 lymphocytes, 19 and platelets 20 ), as well as nonhematopoietic cells (keratinocytes 21 and fibroblasts 22 ), can produce histamine. LPS stimulation upregulates histamine production from macrophages, 17 neutrophils, 18 and keratinocytes. 21 In this study, we showed that the LPS-TLR4 pathway triggered the sneezing response, and clodronate treatment specifically abrogated endotoxin-elicited, but not IgE-mediated, rhinitis. Although we do not clearly exclude the potential off-target effects of clodronate, we believe that depletion of monocytes/macrophages mediates amelioration of Ec-OVA-elicited rhinitis by clodronate. Clodronate might affect dendritic cells, neutrophils, and lymphocytes either directly or indirectly. However, dendritic cells and neutrophils were not depleted, and local T H 2 activation was not compromised by clodronate treatment in our model. These results imply that monocytes/macrophages might be a histamine source in our model, although we did not show a direct link between the monocytes/macrophages and nasal histamine release. If these cells do produce histamine, how they release histamine immediately after endotoxin stimulation should be investigated, because macrophages were reported to release histamine gradually. 17, 44 Because macrophages have specialized roles and tissue-and disease-specific characteristics, 45 ,46 nasal and/or T H 2-activated microenvironments might harbor specific macrophage populations that release histamine immediately in response to endotoxin. Further study is required to clarify how monocytes/macrophages contribute to histamine-mediated nasal immediate-hypersensitivity-like reactions.
Another question suggested by this study is how activated T H 2 cells contribute to the induction of Ec-OVA-elicited rhinitis. We showed that LPS directly triggered sneezing in T H 2-activated noses. However, LPS challenge 48 hours after the antigen exposure failed to elicit sneezing responses regardless of the presence of LPS challenge 24 hours after the antigen exposure. These results suggested that loss of antigen-mediated T-cell activation (eg, by loss of the antigen on dendritic cells in the nose), rather than LPS tolerance, caused the LPS unresponsiveness. Therefore, local T H 2 activation is a prerequisite for inducing endotoxin-elicited rhinitis, and T cells might need to be activated at the time of, or until shortly before, endotoxin exposure. Activated T H 2 cells may activate and/or increase histamine content in nasal cells, such as macrophages, by producing cytokines. Indeed, IL-4 induces tissue macrophage proliferation during T H 2 inflammation, 47 and granulocyte/macrophage-colony stimulating factor increases histidine decarboxylase activity in macrophages. 17 Such cytokines and endotoxin may cooperatively activate nasal histamine production. Further study is required to uncover the molecular mechanisms of T-cell-mediated preparation of the nasal environment that allow it to respond to endotoxin by evoking rhinitis.
We report a novel T-cell-and histamine-mediated type-1-hypersensitivity-like reaction in mice that might participate in classical and mechanism-unknown non-IgE-mediated allergic disorders. Further studies to increase our understanding of the mechanisms involved and broadening the reaction to different organs might indicate novel therapeutic targets as well as aid the development of better diagnostic and classification methods for less well understood allergic(-like) disorders.
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Key messages
d Nasal exposure of endotoxin-containing allergens induces an IgE-independent, yet T-cell-and histamine-dependent, nasal hypersensitivity-like reaction in mice.
d Local activation of antigen-specific CD4 1 T cells followed by nasal endotoxin exposure triggers sneezing responses in mice. 
METHODS Reagents
Recombinant human IL-2, recombinant mouse IL-4, and fluorescein isothiocyanate (FITC)-antimouse-CCR3 mAbs (83101) were purchased from R&D Systems (Minneapolis, Minn). FITC-anti-mouse-B220 mAb (RA3-6B2), FITC-anti-mouse-CD11b mAb (M1/70), FITC-anti-mouseCD11c mAb (HL3), FITC-anti-mouse-CD49b mAb (DX5), phycoerythrinanti-mouse-CD90.2 mAb (53-2.1), and phycoerythrin-anti-mouse-Siglec-F mAb (E50-2440) were purchased from BD Biosciences (San Diego, Calif). FITC-anti-mouse-CD3 mAb (B3B4), FITC-anti-mouse-CD62L mAb (MEL-14), Allophycocyanin (APC)-anti-mouse-DO11.10TCR mAb (KJ1-26), PerCP-Cy5.5-anti-mouse-CD4 mAb (RM4-5), and PacificBlue-anti-mouse-CD45 mAb (30-F11) were purchased from eBiosciences (San Diego, Calif). FITC-anti-mouse-IgE mAb was purchased from SouthernBiotech (Birmingham, Ala). Biotin-anti-mouse-ST2 mAb (DJ8) was purchased from MD Bioproducts (St Paul, Minn). Anti-mouse-IL-12 mAb (C17.8) and anti-mouse-IFN-g mAb (R4-6A2) were prepared in our laboratory. Antidinitrophenyl IgE (SPE-7), OVA (grade V), LPS from Salmonella minnesota 055:B5, aluminum hydroxide hydrate (alum), Triton X-114, and DT from Corynebacterium diphtheriae were purchased from Sigma-Aldrich Japan (Tokyo, Japan). Diphenhydramine hydrochloride was purchased from Wako Pure Chemicals (Osaka, Japan). Fexofenadine hydrochloride was purchased from Tokyo Chemical Industry (Tokyo, Japan). OVA 323-339 peptide was purchased from AnaSpec (Fremont, Calif). Clodronate-containing liposome was purchased from HygieiaBioscience (Osaka, Japan). 
Cell preparation for adoptive transfer
Mouse sneezing analysis
Awake mice were i.n. administered 20 mL of challenge reagents. Immediately after the challenge, each mouse was put in a new cage, a standard breeding cage but without bedding (1 mouse per cage). An investigator directly monitored the mouse behavior for 10 minutes, and each sneezing behavior accompanied with a sneezing sound (see Video E1) was counted. Usually, 2 mice in the different cages were examined at the same time. Randomization and blinding were not used in the experiments.
FACS analysis
Noses were minced with scissors and digested for 50 minutes at 378C with collagenase (150 U/mL) and DNase I (10 mg/mL). After filtration with a cell strainer, red blood cells were lysed from the cell suspension. For staining IgE receptor, cells were incubated with anti-DNP-IgE (1 mg/mL) on ice for 30 minutes. Cells were incubated with antibodies against CCR3, CD4, CD45, CD90.2, DO11.10TCR, Siglec-F, ST2, and Lineage markers (CD3, B220, CD11b, CD11c, DX-5, and IgE) on ice for 30 minutes, and then washed twice with PBS. Stained cells were analyzed by FACSCant II flow cytometer (BD Biosciences) and FlowJo software (version 7.6.1, Tree Star Inc, Ashland, Ore). Singlet CD45 1 cells were gated as nasal hematopoietic cells (Fig E3, A) . CD4 1 DO11.10TCR 1 cells (Fig E3, B) ,
high Siglec-F high cells (Fig E3, C Number of sneezes at day 4 was counted for 10 minutes immediately after the intranasal challenge (mean, SEM, n 5 indicated in figure) . N.S., Not significant. **P < .01; ***P < .001. 
